Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.

ABSTRACT:

Background

Luminal breast cancers with high proliferation (MKS^hi) and low ER-related signalling (ERS^lo) have a poor prognosis. We investigated treatment responses and molecular features of MKS^hi/ERS^lo tumours to inform potential therapies.

Methods

Gene expression data from patients who received neoadjuvant chemotherapy (NAC) without (MDACC, N = 199) or with pembrolizumab (I-SPY2, N = 40), or endocrine therapy (NET) without (POETIC, N = 172) or with palbociclib (NeoPalAna, N = 32) were analyzed to assess treatment response by MKS/ERS-subgroups. TCGA was used to assess the mutational landscape and biomarkers associated with palbociclib-resistance (Cyclin-E, RBsig, IRPR) and immunotherapy-response (TMB, TILs, T-cell inflamed) by MKS/E

SUBMITTER: Licata L 

PROVIDER: S-EPMC10703787 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature